Background
==========

Upper respiratory tract infections (URTIs) can be regarded as a significant problem in childhood; they are the most frequent cause for pediatric visits in general practice, and are mainly reason for antibiotic prescriptions by pediatricians \[[@b1-medscimonit-19-54],[@b2-medscimonit-19-54]\]. *Streptococcus pneumoniae* is one of the major bacterial pathogens colonizing the nasopharynx, and often cause URTIs in children. Adenoids can be regarded as a reservoir of pneumococci \[[@b3-medscimonit-19-54]\]. Contrary to common belief of many pediatricians, the most important pneumococcal infections are of the respiratory tract, not invasive diseases. However, despite the advances in the development of pneumococcal conjugate vaccines (PCVs) leading to a reduction of invasive disorders, eradication of pneumococcal diseases is not within easy reach. Of the 90 pneumococcal serotypes that have been identified so far, the most common ones that cause infections are 3, 6B, 9V, 14, 19F, and 23F. The morbidity of URTIs caused by antibiotic resistant pathogens has been increasing in children, creating a worldwide public health problem. The distribution of resistance among *S. pneumoniae* is of particular interest in the context of introduction of multivalent PCVs. The safety, efficacy and effectiveness in practice of heptavalent pneumococcal conjugate vaccine (PCV-7) and other PCV was established in multiple settings in many countries \[[@b4-medscimonit-19-54],[@b5-medscimonit-19-54]\]. In 2007, World Health Organization (WHO) recommended that all countries incorporate PCV to their national infant immunization program \[[@b6-medscimonit-19-54]\]. PCV-7 was introduced in Poland in 2005 and recommended for children under 2 years old, but is not refunded. Since 2009, the PCV was recommended for children under 5 years old and is refunded for some risk groups.

In this study we investigated the prevalence of *S. pneumoniae* in the nasopharynx and adenoid core in children from Poland who underwent adenoidectomy for recurrent pharyngotonsillitis and we determined serotypes and antibiotic resistance patterns of the isolated pneumococci.

Material and Methods
====================

Patients
--------

The study enrolled 57 children, aged between 2 and 5 years, undergoing adenoidectomy in the Department of Pediatric Otolaryngology, Phoniatrics and Audiology, Medical University of Lublin during May-June 2011. The indication for adenoidectomy was recurrent acute pharyngotonsillitis for at least 2 years, with 5 or more acute attacks per year. Patients did not receive any antibiotic therapy for at least 20 days before the operation. Informed content was obtained from all children's parents. The Ethics Committee of the Medical University of Lublin approved the study protocol (No. KE-0254/75/211).

Demographic data of studied children is shown in [Table 1](#t1-medscimonit-19-54){ref-type="table"}. Each patient received antibiotics 2 or 3 month before surgery. None of the children were immunized with a pneumococcal vaccine.

Laboratory procedures
---------------------

Before adenoidectomy, the nasopharyngeal specimens were obtained with sterile alginate-tipped swabs on aluminium shafts. The surgeon removed the adenoids through the mouth by making several small incisions and cauterized the site once the adenoids were removed. Antiseptic and/or bactericidal agents were not used during the surgery. After the surgery, the adenoids were placed in a sterile container and with the nasopharyngeal swabs were transported 2 hours to the laboratory. One surface of the adenoid was cauterized with a heated scalpel and an incision was made through that cauterized area with a sterile scalpel, cutting the adenoid in half. The core was swabbed with sterile alginate-tipped applicator. Swabs were inoculated on Mueller-Hinton agar with 5% sheep blood and 0.5 mg/L of gentamicin for selective cultivation of streptococci. The streaked agar plates were incubated aerobically at 35°C in 5% CO~2--~-enriched atmosphere for 24 to 48 hours. Pneumococci were identified by colony morphology, susceptibility to Optochin (5 μg), and bile solubility; identification was confirmed by the Slidex Pneumo-Kit (BioMerieux) slide agglutination test.

All isolates were serotyped by Quellung reaction using antisera provided by Statens Serum Institute (Copenhagen, Denmark). We used antisera for determination of serotypes belonging to the 23-valent pneumococcal polysaccharide vaccine (PPV23) (ie, 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) and also serotypes 6A, 23A. The isolates negative to employed pooled sera but positive to omni serum were defined as nontypeable (NT). The untypeable isolates (rough −R) were confirmed by PCR analysis using primers for detecting the *lytA* gene encoding the autolysin enzyme specific to *S. pneumoniae*\[[@b7-medscimonit-19-54]\].

Susceptibility of the isolates to oxacillin, erythromycin (E), tetracycline (Te), chloramphenicol (C), clindamycin (Cc), Norfloxacin (Nor), rifampicin (Ra), teicoplanin (Tec), linezolid (Lzd), and trimethoprim-sulfamethoxazole (Sxt) was determined by the disk diffusion method of Bauer and Kirby. Results were interpreted according to the 2011 European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations \[[@b8-medscimonit-19-54]\]. Isolates exhibiting a zone of ≥20 mm around a 1 μg oxacillin disk were reported as penicillin susceptible *S. pneumoniae* (PSSP); isolates exhibiting a zone of \<20 mm were further tested by the E-test (AB Biodisk, Sweden), following the manufacturer's instruction, to determine minimal inhibitory concentration (MIC) for benzylpenicillin. Isolates with MIC ≤0.064 mg/L were considered as fully susceptible to benzylpenicillin; isolates with MIC \>0.064 mg/L were called penicillin non-susceptible *S. pneumoniae* (PNSSP). Multidrug-resistant isolates of *S. pneumoniae* (MDR-SP) were defined as having resistance to at least 3 different classes of antibiotics. *S. pneumoniae* ATCC 49619 was used as a control strain in the antimicrobial susceptibility tests.

Statistical analysis
--------------------

Data processing and analysis were performed using StatSoft, Inc. STATISTICA 10. The potential predictor variables were: age (years), gender, having siblings, passive smoking, day care center attendance, place of residence, and antibiotics taken for the last attack; these, were tested in separate univariate analyses (Chi-square or Fisher's exact test, as appropriate) for their association with nasopharyngeal and/or adenoid colonization by *S. pneumoniae* in general, and by PNSSP or MDR-SP. Significant univariate predictors (p\<0.1) were tested for inclusion in the multivariate models, and nonsignificant variables were removed sequentially until only those significant at p\<0.1 remained. Variables of particular interest based on previous studies (eg, child age, having siblings, and type of antibiotic used) were included even when were not statistically significant. Results of logistic regression analysis are reported as adjusted odds ratio (OR) with 95%CI. Statistical significance was set at p\<0.05.

Results
=======

*S. pneumoniae* colonization of nasopharynx and/or adenoid core were observed in 40 (70.2%) children who had undergone adenoidectomy for recurrent pharyngotonsillitis. From 29 (50.9%) children, *S. pneumoniae* was isolated both from nasopharynx and adenoid core, and 2 or 3 different isolates were identified in 8 (14.0%) children. In 8 (14.0%) children, *S. pneumoniae* isolates were obtained from adenoid core only and in 3 (5.3%) children from nasopharynx only.

Demographic data of studied children are shown in [Table 1](#t1-medscimonit-19-54){ref-type="table"}. According to multivariate analysis, female sex (p=0.02, OR 6.7, 95% CI 1.3--35.6) and city residence (p=0.02, OR 5.6, 95% CI 1.2--25.0) were the independent factors significantly increasing the carriage rates. When risk factors were analyzed for adenoid core colonization and nasopharyngeal colonization separately, no statistical significance was found.

A total of 51 isolates were recovered. Among the isolates, serotypes of PPV23 (82.4%) were identified; whereas 4 isolates (7.8%) were defined as NT-nontypeable, and 5 isolates (9.8%) were untypable (rough -- R) ([Table 2](#t2-medscimonit-19-54){ref-type="table"}). Identification of all untypable, non-capsulated pneumococci was confirmed by detection of the *lytA* gene encoding the autolysin enzyme specific to *S. pneumoniae*. The most frequent was serotype 19F (25.5%). The prevalence of serotypes included in PCV10 (containing serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) and PCV13 (containing serotypes 3, 6A, 19A additionally to 10-valent vaccine) was 51.0% and 62.7%, respectively.

Among the pneumococcal strains, 35.3% were susceptible to all tested antimicrobial agents belonging to serotypes 3 (5 isolates), 6A (1 isolate), 10A (1 isolate), 11A (2 isolates), 15 non-B (1 isolate), 19F (1 isolate), and NT (4 isolates). Decreased susceptibility to penicillin was observed in 45.1% of strains (MIC range 0.12--2.0 mg/L, MIC~50~ 0.5 mg/L and MIC~90~ 2.0 mg/L). High rates of antibiotic resistance were found: co-trimoxazole -- 52.9%, tetracycline -- 43.1%, erythromycin -- 52.9%, clindamycin -- 51.0%, and chloramphenicol -- 43.1% ([Table 2](#t2-medscimonit-19-54){ref-type="table"}). All isolates were susceptible to norfloxacin and. according to EUCAST 2011, they can be reported as susceptible to levofloxacin and moxifloxacin and intermediate to ciprofloxacin and ofloxacin.

None of the tested isolates was resistant to rifampicin, linezolid, or teicoplanin. Multidrug resistance (MDR) was present in 52.9% of all isolates. Among MDR-SP, 77.8% were non-susceptible to penicillin. PNSSP and MDR-SP strains were mostly distributed among PCV13 serotypes (78.3% and 77.8%, respectively). Neither PNSSP carriage (39.3%) nor MDR-SP carriage (46.4%) were associated with type of antibiotic therapy during the 3 months before adenoidectomy and other analyzed predictors. There were no significant discrepancies concerning serotype and antibiotic resistance distribution between groups of pneumococci isolated from the nasopharynx and adenoid core ([Table 3](#t3-medscimonit-19-54){ref-type="table"}).

A comparison of phenotypes of paired pneumococcal samples obtained from the nasopharynx and adenoid demonstrated that in 24 children (60% of colonized children) an identical phenotypically strain was present. Five children (12.5% of colonized children) were carriers of 2 or 3 phenotypically different strains in the adenoid and in nasopharynx ([Table 4](#t4-medscimonit-19-54){ref-type="table"}).

Discussion
==========

We found a high frequency of *S. pneumoniae* colonization in the upper respiratory tracts of preschool children with recurrent upper respiratory infections. Because of the high rate of asymptomatic pneumococcal carriage in preschool children, especially those attending day care, it is difficult to indicate that *S. pneumoniae* is an important bacterial etiological agent of URTIs \[[@b2-medscimonit-19-54]\]. Jeong et al. \[[@b9-medscimonit-19-54]\] analyzed the differences between the bacterial pathogens of the tonsil core in recurrent tonsillitis and tonsillar hypertrophy with regard to age; *S. pneumoniae* was detected more often in recurrent tonsillitis in the patients 8--14 years, even though in both groups this pathogen was more common in younger patients (\<8 years). However, it is well known that frequent RTIs, mainly of viral etiology, which may injure the mucous membrane and cause damage of the local immunological host response, facilitate adherence of bacteria \[[@b10-medscimonit-19-54]--[@b13-medscimonit-19-54]\]. Syrjanen et al. \[[@b14-medscimonit-19-54]\] reported that nasopharyngeal carriage of pneumococci during RTIs (without otitis media) in children increased from 13--43% to 45--56%, depending on age. In contrast, Greenberg et al. \[[@b15-medscimonit-19-54]\] found no differences in the overall *S. pneumoniae* carriage between healthy and sick children in different age groups. Brook et al. \[[@b16-medscimonit-19-54]\] study showed that cores of "normal" adenoids of healthy children contain polymicrobial aerobic and anaerobic flora similar to the flora found in adenoids of patients with recurrent otitis media, recurrent adeno-tonsillitis, and obstructive adenoid hyperplasia. However, the concentration of most aerobic pathogens (*S. pneumoniae, Staphylococcus aureus, Hemophilus influenzae, and Moraxella catarrhalis*) was lower in the "normal" adenoids of the control group, as compared with all other groups. Karlidag et al. \[[@b17-medscimonit-19-54]\] demonstrated higher prevalence of bacterial pathogens in the adenoid tissue cultures in patients with otitis media with effusion (study group) in comparison to patients with adenotonsillar hyperthrophy (control group) -- *S. pneumoniae* -- 43.9% *vs.* 28%, *H. influenzae* -- 36.6% *vs.* 16% and *M. catarrhalis* -- 17.1% *vs.* 4%. The detection rate of *S. pneumoniae* in the adenoid core was higher than that in the nasopharynx (71.9% *vs.* 61.4%) in our study. This indicates that in children with recurrent upper respiratory infections, pneumococci mostly colonized the tissue of adenoids, which may be recognized as the main reservoir of *S. pneumoniae.* The presence of this pathogen can be one of the causes of chronically infected, swollen, and inflamed adenoids.

In our study, *S. pneumoniae* strains were isolated from the adenoid or nasopharynx in 27.5% of patients, and in 75% of patients from both sites (2 or 3 isolates). These data are comparable to those demonstrated by Tonnaer et al. \[[@b18-medscimonit-19-54]\], who collected pneumococcal cultures from middle ear fluid, oropharynx, and adenoid biopsy from the same patient. These authors \[[@b18-medscimonit-19-54]\] found genetic similarity in the majority of the paired pneumococcal samples obtained from the same patient (80--90%), which indicate clonal relatedness and suggest that pneumococci presenting at different sites in the upper respiratory region of a patient originate from a single source, most likely the nasopharynx or throat. In our study, a comparison of phenotypes of paired pneumococcal samples obtained from the nasopharynx and adenoid of 1 child demonstrated that in 24 (60%) children an identical phenotypically strain was present.

Longitudinal studies have demonstrated that children are successively colonized with multiple strains of pneumococci \[[@b19-medscimonit-19-54],[@b20-medscimonit-19-54]\]. However, identification of simultaneous carriage of multiple serotypes is laborious, and the yield varies according to the method used \[[@b20-medscimonit-19-54],[@b21-medscimonit-19-54]\]. In our study, 2 or 3 different phenotypically strains were identified in 8 (14.0%) children. Carriage of multiple pneumococcal serotypes is an important phenomenon concomitant with the increase in the carriage of non-vaccine serotypes. Eradication of the vaccine serotypes allows exposure of the serotypes that are present, but in lower concentration relative to the vaccine serotypes \[[@b21-medscimonit-19-54]\]. Since *S. pneumoniae* is naturally competent for transformation and inter- and intra-species horizontal gene transfer by homologous recombination, selection of non-vaccine serotypes could be due to subsequent serotype switching during simultaneous carriage of vaccine and non-vaccine pneumococcal strains under vaccination pressure or that lost the capsule. Among 8 children of our study with multiple strain carriage, in 3 children the second/third co-colonized strain was rough and multidrug resistant, probably after losing the capsule. In 6 (75%) children, from nasopharyngeal samples and in 3 (37.5%) children from adenoid core samples, co-colonized strains belonged to non- vaccine serotypes. These strains could be successful in colonization after vaccination.

Community-acquired respiratory tract infections remain the leading cause of physician office visits and use of antimicrobial agents, which are usually administered empirically. Reports of increasing resistance of *S. pneumoniae* to many antimicrobial agents have made treatment management more difficult. The percentage of PNSSP isolates has been reported to be 0%--60% among healthy children in Europe \[[@b14-medscimonit-19-54],[@b20-medscimonit-19-54],[@b22-medscimonit-19-54]--[@b24-medscimonit-19-54]\]. Data presented in this study confirmed that prevalence of PNSSP in Poland has been constantly increasing. In the recent Alexander Project, conducted from 1998 to 2000, the frequency of PNSSP was 12.3% \[[@b25-medscimonit-19-54]\], but a significant increase to 20.3% was observed among clinical isolates in 2002 \[[@b26-medscimonit-19-54]\]. However, at the same time in Poland, the percentage of PNSSP isolates from healthy children under 5 years old in settings such as day care centers (DCCs) and orphanages was 36.2% \[[@b23-medscimonit-19-54]\]. The prevalence of erythromycin resistance exceeded that of penicillin resistance in the majority of countries, as in our study \[[@b25-medscimonit-19-54]\]. The prevalence of both penicillin-resistant and erythromycin-resistant *S. pneumoniae* in our study was high (41.2%), consistent with findings from other surveillance studies \[[@b25-medscimonit-19-54],[@b27-medscimonit-19-54]\]. An alarmingly high prevalence of MDR pneumococcal strains was observed in our study (55%), higher than was noted by other authors \[[@b19-medscimonit-19-54],[@b25-medscimonit-19-54]\].

Infections cause by drug resistant pathogens in the nasopharynx or the adenoids seems to be harder to treat medically, which could result in the need for adenoidectomy, which seems to have a beneficial effect on the nasopharyngeal bacterial flora \[[@b28-medscimonit-19-54]\]. Aarts et al. \[[@b28-medscimonit-19-54]\] demonstrated that *S. pneumoniae* and *H. influenza* were most often detected in the nasopharynx of children with recurrent URTIs, and carriage of these bacteria decreased after adenoidectomy in the majority of studies.

Children with recurrent pharyngotonsillitis are usually treated with multiple courses of antibiotics before surgery, but many of them continue to carry pathogenic bacteria in the pharynx and the adenoids, including strains resistant to antibiotics \[[@b3-medscimonit-19-54]\]. Although all of the children from our studies were treated by antibiotics, a high prevalence of resistant pneumococci was observed. On the other hand, the increase in antibiotic resistance of *S. pneumoniae* is generally attributed to the extensive use of antibiotics and the selective pressure on the bacterial strains of the nasopharyngeal flora \[[@b29-medscimonit-19-54]\]. There were no connections between presence of antibiotic-resistant strains and type of antibiotic taken by children in our study. Most children in our study attended day care centers (92.7%), which are recognized as places of successful transmission of pneumococci from person to person, including drug-resistant strains, irrespective of antibiotic therapy \[[@b22-medscimonit-19-54]\]. That may be the explanation of lack of association between the use of any antibiotic type and pneumococcal carriage, as well as recovery of resistant strains.

However, some studies demonstrated an association between the use of a specific antibiotic and selective colonization by pathogens resistant to that drug \[[@b22-medscimonit-19-54],[@b30-medscimonit-19-54]\]; the number of courses of drugs to which pathogens are resistant has the utmost importance \[[@b22-medscimonit-19-54]\].

Worldwide, the clonal dissemination of a small group of MDR clones of *S. pneumoniae* produces the majority of clinical treatment failures \[[@b30-medscimonit-19-54]\]. The WHO considers immunization of infants and young children with pneumococcal vaccines a priority. Data published by other authors suggested that vaccination could potentially reduce the carriage rate of antibiotic-resistant pneumococci in Europe \[[@b23-medscimonit-19-54],[@b31-medscimonit-19-54]\]. Currently, in Poland, the 23-valent polysaccharide vaccine for children ≥2 years old and adults (since 1996), and pneumococcal conjugate vaccines (PCV7 \[since 2006\], PCV10 \[since 2009\], and PCV13 \[since 2010\] for children ≤2 years old, have been recommended in the national immunization schedule. Since 2006, less than 5% of children ≤5 years were vaccinated per year, so currently we suppose that less than 15% of children in this group of age are immunized with PCV \[[@b32-medscimonit-19-54]\]. PCV7 is currently being replaced by PCV13 vaccine as manufacturing and supply are scaled up. An encouraging finding of our study was that a majority of PNSSP and MDR-SP belonged to serotypes included in PCV13 and PCV10.

According to studies performed in Poland \[[@b33-medscimonit-19-54]--[@b35-medscimonit-19-54]\] there were high invasive pneumococcal disease (IPD) incidence rates among children under 5 years of age. PCV10 and PCV13 covered 71.2--76.3%, and 86.3--92.3%, respectively, of cases involving children under 5 years of age \[[@b33-medscimonit-19-54],[@b34-medscimonit-19-54]\]. The above data suggest that routine vaccination of infants with PCVs could effectively reduce the carriage rate of pneumococci, including drug-resistant strains, in children in Poland, as in other European countries \[[@b5-medscimonit-19-54]\].

Conclusions
===========

A high prevalence of *S. pneumoniae* colonization in the nasopharynx and adenoids in children with recurrent URTIs was observed and a high rate of resistance to macrolides and β-lactams of isolates was demonstrated. Over half of the isolates were classified as MDR-SP. There is a possibility that the adenoids, like the nasopharynx, are acting as a reservoir of pneumococci, including drug-resistant strains, especially in children with indication for adenoidectomy due to recurrent respiratory tract infections refractory to antibiotic therapy. Good vaccine coverage among the isolated pneumococci confirmed the validity of the introduction of PCVs in the national immunization programme for all children younger than 5 years of age. This procedure could significantly reduce pneumococcal related morbidity, especially that caused by pneumococci not susceptible to antibiotics.
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###### 

Demographic data of children undergoing adenoidectomy for recurrent URTIs.

                                          Risk factor                 SP colonized children (%)   SP uncolonized children (%)   Univariate analysis *p*   Multivariate analysis *p*
  --------------------------------------- --------------------------- --------------------------- ----------------------------- ------------------------- ---------------------------
  Age (yr)                                2                           3 (75.0)                    1 (25.0)                      0.48                      
  3                                       3 (42.9)                    4 (57.1)                                                                            
  4                                       26 (72.2)                   10 (27.8)                                                                           
  5                                       7 (70.0)                    3 (30.0)                                                                            
  Sex                                     Female                      17 (85.0)                   3 (15.0)                      0.073                     0.021
  Male                                    22 (59.5)                   15 (40.5)                                                                           
  Sibling possessing                      No                          7 (70.0)                    3 (30.0)                      1.0                       
  1                                       19 (67.9)                   9 (32.1)                                                                            
  ≥2                                      13 (68.4)                   6 (31.6)                                                                            
  Passive smoking                                                     13 (59.1)                   26 (74.3)                     0.26                      
  DCC attendance                                                      34 (66.7)                   3 (75.0)                      1.0                       
  Place of residence                      Village                     8 (50.0)                    8 (50.0)                      0.06                      0.022
  City                                    31 (75.6)                   10 (24.4)                                                                           
  Antibiotics taken for the last attack   Amoxicillin/ co-amoxiclav   22 (71.0)                   9 (29.0)                      0.72                      
  Cephalosporins                          9 (69.2)                    4 (30.8)                                                                            
  Macrolides                              7 (58.3)                    5 (41.7)                                                                            

DCC -- day care center; SP -- *Streptococcus pneumoniae.*

###### 

Antibiotic resistance in *Streptococcus pneumoniae* isolated from nasopharynx and/or adenoid core of children undergoing adenoidectomy for recurrent URTIs.

  Antibiotic        No. of resistant isolates (%)   Serotypes (no. of isolates)
  ----------------- ------------------------------- -------------------------------------------------------------------------
  Penicillin        23 (45.1)                       9V (1), 14 (3), 6B (3), 19F (6), 23F (5), R (5)
  Erythromycin      27 (52.9)                       6B (3), 14 (3), 15-nonB (1), 19F (10), 22F (1), 23F (5), R (4)
  Clindamycin       26 (51.0)                       6B (3), 14 (2), 15-nonB (1), 19F (10), 22F (1), 23F (5), R (4)
  Tetracycline      22 (43.1)                       6B (1), 14 (1), 10A (1), 15-nonB (1), 19F (11), 22F (1), 23F (2), R (4)
  Chloramphenicol   22 (43.1)                       6B (3), 10A (1), 19F (9), 23F (5), R (4)
  Co-trimoxazole    27 (52.9)                       9V (1), 6B (3), 14 (2), 19F (10), 23F (6), R (5)
  Norfloxacin       None                            None
  Rifampicin        None                            None
  Teicoplanin       None                            None
  Linezolid         None                            None
  MDR               28 (54.9)                       6B (3), 14 (2), 15-nonB (1), 19 F (11), 22F (1), 23F (5), R (5)

R -- rough, untypeable strain; NT -- nontypeable; MDR -- multidrug resistant.

###### 

Distribution of serotype and antibiotic resistance in *Streptococcus pneumoniae* isolated from nasopharynx (NP) and adenoid core (AD) samples of children undergoing adenoidectomy for recurrent URTIs.

  Site of isolation   Resistance to antibiotics No (%) of isolates   Serotypes No (%) of isolates                                                                                                                                                                                
  ------------------- ---------------------------------------------- ------------------------------ ----------- ----------- ----------- ----------- ---------- --------- --------- --------- --------- --------- --------- ---------- ----------- --------- ---------- --------- ---------
  NP (n=35)           14 (40.0)                                      19 (54.3)                      18 (51.4)   16 (45.7)   10 (28.6)   17 (48.6)   4 (11.4)   0 (0)     1 (2.9)   1 (2.9)   2 (5.7)   0 (0)     3 (8.6)   4 (11.4)   10 (28.6)   1 (2.9)   3 (8.6)    3 (8.6)   3 (8.6)
                                                                                                                                                                                                                                                                                 
  AD (n=41)           20 (48.8)                                      21 (51.2)                      21 (51.2)   15 (36.6)   15 (36.6)   25 (61.0)   5 (12.2)   1 (2.4)   3 (7.3)   1 (2.4)   2 (4.9)   1 (2.4)   2 (4.9)   2 (4.9)    11 (26.8)   0 (0)     6 (14.6)   3 (7.3)   4 (9.8)

P -- penicillin; E -- erythromycin; Cc -- clindamycin; Te -- tetracycline; C -- chloramphenicol; Sxt -- co-trimoxazole; R -- rough, untypeable strain; NT -- nontypeable.

###### 

Characteristics of multiple co-colonization by *Streptococcus pneumoniae* isolated from nasopharynx and/or adenoid core of eight children undergoing adenoidectomy for recurrent URTIs.

  No. of sample   Phenotypes of isolates from   
  --------------- ----------------------------- ----------------
  9               3 S                           3 S
                                                
  NT S                                          
                                                
  15              19F TeCSxt                    19F TeCSxt
                                                
  R PECcTeSxt                                   
                                                
  30              11A S                         11A S
                                                
  R PECcTeSxt     R PECcTeSxt                   
                                                
  36              19F ECcTe                     23F Sxt
                                                
  43              19F PeCcTeSxt                 15-nonB S
                                                
  49              15-nonB S                     19F PECcTeCSxt
                                                
  R PECcTeSxt                                   
                                                
  52              15-nonB ECcTe                 19F S
                                                
  3 S             3 S                           
                                                
  63              22F ECcTe                     23F PECcCSxt

S -- susceptible to all tested antibiotics; P -- penicillin; E -- erythromycin; Cc -- clindamycin; Te -- tetracycline; C -- chloramphenicol; Sxt -- co-trimoxazole; R -- rough, untypeable strain; NT -- nontypeable.
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